Literature DB >> 23817611

Severity of allergic airway disease due to house dust mite allergen is not increased after clinical recovery of lung infection with Chlamydia pneumoniae in mice.

Pavel Dutow1, Sandra Lingner, Robert Laudeley, Silke Glage, Heinz-Gerd Hoymann, Anna-Maria Dittrich, Beate Fehlhaber, Meike Müller, Armin Braun, Andreas Klos.   

Abstract

Chlamydia pneumoniae is associated with chronic inflammatory lung diseases like bronchial asthma and chronic obstructive pulmonary disease. The existence of a causal link between allergic airway disease and C. pneumoniae is controversial. A mouse model was used to address the question of whether preceding C. pneumoniae lung infection and recovery modifies the outcome of experimental allergic asthma after subsequent sensitization with house dust mite (HDM) allergen. After intranasal infection, BALB/c mice suffered from pneumonia characterized by an increased clinical score, reduction of body weight, histopathology, and a bacterial load in the lungs. After 4 weeks, when infection had almost resolved clinically, HDM allergen sensitization was performed for another 4 weeks. Subsequently, mice were subjected to a methacholine hyperresponsiveness test and sacrificed for further analyses. As expected, after 8 weeks, C. pneumoniae-specific antibodies were detectable only in infected mice and the titer was significantly higher in the C. pneumoniae/HDM allergen-treated group than in the C. pneumoniae/NaCl group. Intriguingly, airway hyperresponsiveness and eosinophilia in bronchoalveolar lavage fluid were significantly lower in the C. pneumoniae/HDM allergen-treated group than in the mock/HDM allergen-treated group. We did observe a relationship between experimental asthma and chlamydial infection. Our results demonstrate an influence of sensitization to HDM allergen on the development of a humoral antibacterial response. However, our model demonstrates no increase in the severity of experimental asthma to HDM allergen as a physiological allergen after clinically resolved severe chlamydial lung infection. Our results rather suggest that allergic airway disease and concomitant cellular changes in mice are decreased following C. pneumoniae lung infection in this setting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23817611      PMCID: PMC3754214          DOI: 10.1128/IAI.00334-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

1.  Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma.

Authors:  P N Black; R Scicchitano; C R Jenkins; F Blasi; L Allegra; J Wlodarczyk; B C Cooper
Journal:  Eur Respir J       Date:  2000-02       Impact factor: 16.671

Review 2.  Role of atypical bacterial infection of the lung in predisposition/protection of asthma.

Authors:  Philip M Hansbro; Kenneth W Beagley; Jay C Horvat; Peter G Gibson
Journal:  Pharmacol Ther       Date:  2004-03       Impact factor: 12.310

Review 3.  The role of T lymphocytes in asthma.

Authors:  A Barry Kay
Journal:  Chem Immunol Allergy       Date:  2006

Review 4.  Asthma control in adults.

Authors:  John Rees
Journal:  BMJ       Date:  2006-04-01

Review 5.  The role of T lymphocytes in the pathogenesis of asthma.

Authors:  Mark Larché; Douglas S Robinson; A Barry Kay
Journal:  J Allergy Clin Immunol       Date:  2003-03       Impact factor: 10.793

6.  Effects of respiratory Mycoplasma pneumoniae infection on allergen-induced bronchial hyperresponsiveness and lung inflammation in mice.

Authors:  Hong Wei Chu; Joyce M Honour; Catherine A Rawlinson; Ronald J Harbeck; Richard J Martin
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

Review 7.  New developments in lung function measurements in rodents.

Authors:  Heinz-Gerd Hoymann
Journal:  Exp Toxicol Pathol       Date:  2006-04-17

8.  Prior exposure to live Mycobacterium bovis BCG decreases Cryptococcus neoformans-induced lung eosinophilia in a gamma interferon-dependent manner.

Authors:  Gerhard Walzl; Ian R Humphreys; Ben G Marshall; Lorna Edwards; Peter J M Openshaw; Rory J Shaw; Tracy Hussell
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

Review 9.  The role of innate immunity in asthma: leads and lessons from mouse models.

Authors:  N W J Schröder; M Maurer
Journal:  Allergy       Date:  2007-06       Impact factor: 13.146

Review 10.  Allergies, infections and the hygiene hypothesis--the epidemiological evidence.

Authors:  Erika von Mutius
Journal:  Immunobiology       Date:  2007-04-30       Impact factor: 3.144

View more
  5 in total

1.  The complement C3a receptor is critical in defense against Chlamydia psittaci in mouse lung infection and required for antibody and optimal T cell response.

Authors:  Pavel Dutow; Beate Fehlhaber; Jenny Bode; Robert Laudeley; Claudia Rheinheimer; Silke Glage; Rick A Wetsel; Oliver Pabst; Andreas Klos
Journal:  J Infect Dis       Date:  2013-11-23       Impact factor: 5.226

2.  Characteristics of Allergic Pulmonary Inflammation in CXCR3Knockout Mice Sensitized and Challenged with House Dust Mite Protein.

Authors:  Zhongjuan Liu; Huaxia Chen; Xiaolan Chen; Jinming Gao; Zijian Guo
Journal:  PLoS One       Date:  2016-10-11       Impact factor: 3.240

3.  Effect of pidotimod combined with azithromycin on children with mycoplasma pneumonia and the expression levels of IL-10 and G-CSF in serum.

Authors:  Hongxing Shi; Limin Lan; Xianghong Lv; Lizhi Sun
Journal:  Exp Ther Med       Date:  2019-07-03       Impact factor: 2.447

4.  Complement and Chlamydia psittaci: Early Complement-Dependent Events Are Important for DC Migration and Protection During Mouse Lung Infection.

Authors:  Martin Kohn; Christian Lanfermann; Robert Laudeley; Silke Glage; Claudia Rheinheimer; Andreas Klos
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

5.  Complement and Chlamydia psittaci: Non-Myeloid-Derived C3 Predominantly Induces Protective Adaptive Immune Responses in Mouse Lung Infection.

Authors:  Martin Kohn; Christian Lanfermann; Robert Laudeley; Silke Glage; Claudia Rheinheimer; Andreas Klos
Journal:  Front Immunol       Date:  2021-03-04       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.